Cell-based regenerative medicine for renovascular disease

Trends Mol Med. 2021 Sep;27(9):882-894. doi: 10.1016/j.molmed.2021.06.004. Epub 2021 Jun 25.

Abstract

Renal artery stenosis (RAS) elicits the development of hypertension and post-stenotic kidney damage, which may become irresponsive to restoration of arterial patency. Rather than mere losses of blood flow or oxygen supply, irreversible intrarenal microvascular rarefaction, tubular injury, and interstitial fibrosis are now attributed to intrinsic pathways activated within the kidney, focusing attention on the kidney parenchyma as a therapeutic target. Several regenerative approaches involving the delivery of reparative cells or products have achieved kidney repair in experimental models of RAS and the delivery of mesenchymal stem/stromal cells (MSCs) has already been translated to human subjects with RAS with promising results. The ongoing development of innovative approaches in kidney disease awaits application, validation, and acceptance as routine clinical treatment to avert kidney damage in RAS.

Trial registration: ClinicalTrials.gov NCT00081731 NCT02266394.

Keywords: hypertension; mesenchymal stem/stromal cells; regeneration; renovascular disease.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

Associated data

  • ClinicalTrials.gov/NCT00081731
  • ClinicalTrials.gov/NCT02266394